Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma

Abstract Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qi-Fan Yang, Di Wu, Jian Wang, Li Ba, Chen Tian, Yu-Ting Liu, Yue Hu, Li Liu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e3d3131177f044b8a16fa6a095441956
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e3d3131177f044b8a16fa6a095441956
record_format	dspace
spelling	oai:doaj.org-article:e3d3131177f044b8a16fa6a0954419562021-12-02T16:04:18ZDevelopment and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma10.1038/s41598-021-92115-02045-2322https://doaj.org/article/e3d3131177f044b8a16fa6a0954419562021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92115-0https://doaj.org/toc/2045-2322Abstract Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five public datasets, consisting of 687 cases, we developed an immune-related prognostic model (IPM) according to immune genes from ImmPort database. Then, we comprehensively analyzed the immune microenvironment and mutation burden that are significantly associated with this model. According to the IPM, patients were stratified into high- and low-risk groups with markedly distinct survival benefits. We found that patients with high immune risk possessed a higher proportion of immunosuppressive cells such as macrophages M0, and presented higher expression of CD47, CD73, SIRPA, and TIM-3. Moreover, When further stratified based on the tumor mutation burden (TMB) and risk score, patients with high TMB and low immune risk had a remarkable prolonged overall survival compared to patients with low TMB and high immune risk. Finally, a nomogram combing the IPM with clinical factors was established to provide a more precise evaluation of prognosis. The proposed immune relevant model is a promising biomarker for predicting overall survival in stage I–III LUSC. Thus, it may shed light on identifying patient subset at high risk of adverse prognosis from an immunological perspective.Qi-Fan YangDi WuJian WangLi BaChen TianYu-Ting LiuYue HuLi LiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Qi-Fan Yang Di Wu Jian Wang Li Ba Chen Tian Yu-Ting Liu Yue Hu Li Liu Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
description	Abstract Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five public datasets, consisting of 687 cases, we developed an immune-related prognostic model (IPM) according to immune genes from ImmPort database. Then, we comprehensively analyzed the immune microenvironment and mutation burden that are significantly associated with this model. According to the IPM, patients were stratified into high- and low-risk groups with markedly distinct survival benefits. We found that patients with high immune risk possessed a higher proportion of immunosuppressive cells such as macrophages M0, and presented higher expression of CD47, CD73, SIRPA, and TIM-3. Moreover, When further stratified based on the tumor mutation burden (TMB) and risk score, patients with high TMB and low immune risk had a remarkable prolonged overall survival compared to patients with low TMB and high immune risk. Finally, a nomogram combing the IPM with clinical factors was established to provide a more precise evaluation of prognosis. The proposed immune relevant model is a promising biomarker for predicting overall survival in stage I–III LUSC. Thus, it may shed light on identifying patient subset at high risk of adverse prognosis from an immunological perspective.
format	article
author	Qi-Fan Yang Di Wu Jian Wang Li Ba Chen Tian Yu-Ting Liu Yue Hu Li Liu
author_facet	Qi-Fan Yang Di Wu Jian Wang Li Ba Chen Tian Yu-Ting Liu Yue Hu Li Liu
author_sort	Qi-Fan Yang
title	Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
title_short	Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
title_full	Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
title_fullStr	Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
title_full_unstemmed	Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
title_sort	development and validation of an individualized immune prognostic model in stage i–iii lung squamous cell carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e3d3131177f044b8a16fa6a095441956
work_keys_str_mv	AT qifanyang developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT diwu developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT jianwang developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT liba developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT chentian developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT yutingliu developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT yuehu developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT liliu developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma
_version_	1718385240527863808

Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma

Ejemplares similares